The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Bisphosphonate Use and the Risk of Subtrochanteric or Femoral Shaft Fractures in Older Women
Abstract
CONTEXT: Osteoporosis is associated with significant morbidity and mortality. Oral bisphosphonates have become a mainstay of treatment, but concerns have emerged that long-term use of these drugs may suppress bone remodeling, leading to unusual fractures. OBJECTIVE: To determine whether prolonged bisphosphonate therapy is associated with an increased risk of subtrochanteric or femoral shaft fracture. DESIGN, SETTING, AND PATIENTS: A population-based, nested case-control study to explore the association between bisphosphonate use and fractures in a cohort of women aged 68 years or older from Ontario, Canada, who initiated therapy with an oral bisphosphonate between April 1, 2002, and March 31, 2008. Cases were those hospitalized with a subtrochanteric or femoral shaft fracture and were matched to up to 5 controls with no such fracture. Study participants were followed up until March 31, 2009. MAIN OUTCOME MEASURES: The primary analysis examined the association between hospitalization for a subtrochanteric or femoral shaft fracture and duration of bisphosphonate exposure. To test the specificity of the findings, the association between bisphosphonate use and fractures of the femoral neck or intertrochanteric region, which are characteristic of osteoporotic fractures, was also examined. RESULTS: We identified 716 women who sustained a subtrochanteric or femoral shaft fracture following initiation of bisphosphonate therapy and 9723 women who sustained a typical osteoporotic fracture of the intertrochanteric region or femoral neck. Compared with transient bisphosphonate use, treatment for 5 years or longer was associated with an increased risk of subtrochanteric or femoral shaft fracture (adjusted odds ratio, 2.74; 95% confidence interval, 1.25-6.02). A reduced risk of typical osteoporotic fractures occurred among women with more than 5 years of bisphosphonate therapy (adjusted odds ratio, 0.76; 95% confidence interval, 0.63-0.93). Among 52,595 women with at least 5 years of bisphosphonate therapy, a subtrochanteric or femoral shaft fracture occurred in 71 (0.13%) during the subsequent year and 117 (0.22%) within 2 years. CONCLUSION: Among older women, treatment with a bisphosphonate for more than 5 years was associated with an increased risk of subtrochanteric or femoral shaft fractures; however, the absolute risk of these fractures is low.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Shane, E., Burr, D., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., Dempster, D. W., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1998 · Cited by 2,147
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
International statistical classification of diseases and related health problems. Tenth revision.
Brämer, G. R. (1988) · PubMed · Cited by 1,492
Black, D. M., Schwartz, A. V., Ensrud, K. E., Cauley, J. A., Levis, S., Quandt, S. A., Satterfield, S., Wallace, R. B., Bauer, D. C., Palermo, L., et al. (2006) · JAMA · doi:10.1001/jama.296.24.2927 · Cited by 1,407
Meta-analysis: Excess Mortality After Hip Fracture Among Older Women and Men
Haentjens, P., Magaziner, J., Colón-Emeric, C. S., Vanderschueren, D., Milisen, K., Velkeniers, B., & Boonen, S. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-6-201003160-00008 · Cited by 1,398
Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women
Bone, H. G., Hosking, D., Devogelaer, J.-P., Tucci, J. R., Emkey, R. D., Tonino, R. P., Rodriguez-Portales, J. A., Downs, R. W., Gupta, J., Santora, A. C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030897 · Cited by 1,347
Methods in Observational Epidemiology
Kelsey, J. L. (1986) · Cited by 1,307
Methods in observational epidemiology
Leck, I. (1987) · Journal of Epidemiology and Community Health · doi:10.1136/jech.41.3.263-a · Cited by 1,278
Shane, E., Burr, D., Ebeling, P. R., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.253 · Cited by 1,116
Schneeweiss, S. (2001) · American Journal of Epidemiology · doi:10.1093/aje/154.9.854 · Cited by 711
Low-Energy Femoral Shaft Fractures Associated With Alendronate Use
Neviaser, A. S., Lane, J. M., Lenart, B. A., Edobor-Osula, F., & Lorich, D. G. (2008) · Journal of Orthopaedic Trauma · doi:10.1097/bot.0b013e318172841c · Cited by 526
Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur
Black, D. M., Kelly, M. P., Genant, H. K., Palermo, L., Eastell, R., Bucci-Rechtweg, C., Cauley, J., Leung, P. C., Boonen, S., Santora, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001086 · Cited by 512
Wells, G. A., Cranney, A., Peterson, J., Boucher, M., Shea, B., Welch, V., Coyle, D., & Tugwell, P. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003376.pub3 · Cited by 499
Adverse effects of bisphosphonates: Implications for osteoporosis management
Kennel, K. A., & Drake, M. T. (2009) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60752-0 · Cited by 496
(2003) · PubMed · Cited by 490
A systematic review of persistence and compliance with bisphosphonates for osteoporosis
Cramer, J. A., Gold, D. T., Silverman, S. L., & Lewiecki, E. M. (2007) · Osteoporosis International · doi:10.1007/s00198-006-0322-8 · Cited by 443
Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study
Ioannidis, G., Papaioannou, A., Hopman, W. M., Akhtar-Danesh, N., Anastassiades, T., Pickard, L., Kennedy, C. C., Prior, J. C., Olszynski, W. P., Davison, K. S., et al. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.081720 · Cited by 432
Biased Selection of Controls for Case-Control Analyses of Cohort Studies
Lubin, J. H., & Gail, M. H. (1984) · Biometrics · doi:10.2307/2530744 · Cited by 414
Wells, G. A., Cranney, A., Peterson, J., Boucher, M., Shea, B., Welch, V., Coyle, D., & Tugwell, P. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001155.pub2 · Cited by 401
Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study
Lenart, B. A., Neviaser, A. S., Lyman, S., Chang, C. C., Edobor-Osula, F., Steele, B., van der Meulen, M. C. H., Lorich, D. G., & Lane, J. M. (2009) · Osteoporosis International · doi:10.1007/s00198-008-0805-x · Cited by 384
Outpatient gatifloxacin therapy and dysglycemia in older adults.
Park-Wyllie, L. Y., Juurlink, D. N., Kopp, A., Shah, B. R., Stukel, T. A., Stumpo, C., Dresser, L., Low, D. E., & Mamdani, M. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055191 · Cited by 367
Self-citationAbrahamsen, B., Eiken, P., & Eastell, R. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081247 · Cited by 366
A heuristic approach to the formulas for population attributable fraction
Hanley, J. A. (2001) · Journal of Epidemiology and Community Health · doi:10.1136/jech.55.7.508 · Cited by 280
Rizzoli, R., Åkesson, K., Bouxsein, M., Kanis, J. A., Napoli, N., Papapoulos, S., Reginster, J.-Y., & Cooper, C. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1453-5 · Cited by 249
Wells, G. A., Cranney, A., Peterson, J., Boucher, M., Shea, B., Welch, V., Coyle, D., & Tugwell, P. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004523.pub3 · Cited by 211
for the CaMos Study Group, Papaioannou, A., Kennedy, C. C., Ioannidis, G., Sawka, A., Hopman, W. M., Pickard, L., Brown, J. P., Josse, R. G., Kaiser, S., et al. (2009) · Osteoporosis International · doi:10.1007/s00198-008-0743-7 · Cited by 191
Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday
Curtis, J. R., Westfall, A. O., Cheng, H. T., Delzell, E., & Saag, K. G. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0604-4 · Cited by 135
Rockhill, B., Weinberg, C. R., & Newman, B. M. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009535 · Cited by 132
Cholinesterase Inhibitors and Hospitalization for Bradycardia: A Population-Based Study
Park‐Wyllie, L. Y., Mamdani, M., Li, P., Gill, S. S., Laupacis, A., & Juurlink, D. N. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000157 · Cited by 124
Self-citationMore on "Biased Selection of Controls for Case-Control Analyses of Cohort Studies"
Robins, J. M., Gail, M. H., & Lubin, J. H. (1986) · Biometrics · doi:10.2307/2531050 · Cited by 116
Evolving Data about Subtrochanteric Fractures and Bisphosphonates
Shane, E. J. (2010) · New England Journal of Medicine · doi:10.1056/nejme1003064 · Cited by 88
Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk.
Schneider, J. P. (2009) · PubMed · Cited by 73
Secular trends in proximal femoral fracture, Oxford record linkage study area and England 1968-86.
Evans, J. G., Seagroatt, V. A., & Goldacre, M. J. (1997) · Journal of Epidemiology & Community Health · doi:10.1136/jech.51.4.424 · Cited by 72
Socioeconomic Misclassification in Ontario’s Health Care Registry
Glazier, R. H., Creatore, M. I., Agha, M., Steele, L. S., Agha, M., Creatore, M. I., Glazier, R. H., Hwang, S. W., Rhodes, A. E., Steele, L. S., et al. (2003) · Canadian Journal of Public Health · doi:10.1007/bf03404588 · Cited by 63
Local and national electronic databases in Norway demonstrate a varying degree of validity
Lofthus, C. M., Cappelen, I., Osnes, E. K., Falch, J. A., Kristiansen, I., Medhus, A. W., Nordsletten, L., & Meyer, H. E. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.07.003 · Cited by 61
To stop or not to stop, that is the question
Seeman, E. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0813-x · Cited by 54
Wang, M., Shugart, Y. Y., Cole, S. R., & Platz, E. A. (2009) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0839 · Cited by 46
Colon-Emeric, C. S. (2006) · JAMA · doi:10.1001/jama.296.24.2968 · Cited by 46
Bisphosphonates for postmenopausal osteoporosis: Determining duration of treatment
Geusens, P. (2009) · Current Osteoporosis Reports · doi:10.1007/s11914-009-0003-6 · Cited by 34
PERSISTENCE WITH BISPHOSPHONATE THERAPY IN OLDER PEOPLE
de Melo, M. N., Qiu, F., Sykora, K., Juurlink, D. N., Laupacis, A., & Mamdani, M. (2006) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2006.00758.x · Cited by 22
Hip fractures in users of first- vs. second-generation bisphosphonates
Mamdani, M., Kopp, A., & HAWKER, G. A. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0446-5 · Cited by 6
Cited by
Shane, E., Burr, D., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., Dempster, D. W., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1998 · Cited by 2,147
Eastell, R., Rosen, C. J., Black, D. M., Cheung, A. M., Murad, M. H., & Shoback, D. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00221 · Cited by 868
Long-term Analgesic Use After Low-Risk Surgery: A Retrospective Cohort Study
Alam, A. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.1827 · Cited by 788
Black, D. M., Reid, I. R., Boonen, S., Bucci-Rechtweg, C., Cauley, J. A., Cosman, F., Cummings, S. R., Hue, T. F., Lippuner, K., Lakatos, P., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1494 · Cited by 700
Majhail, Rizzo, J. D., Lee, S. J., Aljurf, M., Atsuta, Y., Bonfim, C., Burns, L. J., Chaudhri, N., Davies, S., Okamoto, S., et al. (2012) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.5581/1516-8484.20120032 · Cited by 509
Metadata
- Authors
- Park-Wyllie, L. Y.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2011-02-23
- Volume
- 305
- Issue
- 8
- Pages
- 783
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2076490579
- Cited by
- 442
- References
- 42
- FWCI
- 68.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.